Patients were randomized into two groups : group 1 included patients who received rosuvastatin therapy in an average dose of 12.5 mg/day ( n = 16 ) ; group 2 included patients who received combination treatment with atorvastatin in an average dose of 13.3 mg/day and ezetimibe ( 10 mg ) ( n = 15 ) .